Litcius/Paper detail

Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study

Bruce A. Hug, Christopher Matheny, Olivia Burns, Herbert Struemper, Xiaowei Wang, Michael L. Washburn

2020Clinical Therapeutics20 citationsDOIOpen Access PDF

Topics & Concepts

MedicineTolerabilityPharmacodynamicsPlaceboPharmacokineticsAdverse effectPharmacologyInternal medicineAgonistReceptorPathologyAlternative medicineImmune Response and InflammationT-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers
Safety, Pharmacokinetics, and Pharmacodynamics of the TLR4 Agonist GSK1795091 in Healthy Individuals: Results from a Randomized, Double-blind, Placebo-controlled, Ascending Dose Study | Litcius